BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Armenian SH, Gelehrter SK, Chow EJ. Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer. Cardiol Res Pract 2012;2012:713294. [PMID: 22928146 DOI: 10.1155/2012/713294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Mancilla TR, Davis LR, Aune GJ. Doxorubicin-induced p53 interferes with mitophagy in cardiac fibroblasts. PLoS One 2020;15:e0238856. [PMID: 32960902 DOI: 10.1371/journal.pone.0238856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;38:3-12. [PMID: 30231396 DOI: 10.1200/edbk_100015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
3 Morel S, Leahy J, Fournier M, Lamarche B, Garofalo C, Grimard G, Poulain F, Delvin E, Laverdière C, Krajinovic M, Drouin S, Sinnett D, Marcil V, Levy E. Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. J Lipid Res 2017;58:982-93. [PMID: 28274961 DOI: 10.1194/jlr.M072207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
4 Toro-Salazar OH, Gillan E, Ferranti J, Orsey A, Rubin K, Upadhyay S, Mazur W, Hor KN. Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy. Cardiooncology 2015;1:1. [PMID: 33530141 DOI: 10.1186/s40959-015-0005-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Hamilton SN, Carlson R, Hasan H, Rassekh SR, Goddard K. Long-term Outcomes and Complications in Pediatric Ewing Sarcoma. Am J Clin Oncol 2017;40:423-8. [PMID: 25599318 DOI: 10.1097/COC.0000000000000176] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 7.4] [Reference Citation Analysis]
6 Chow EJ, Chen Y, Kremer LC, Breslow NE, Hudson MM, Armstrong GT, Border WL, Feijen EA, Green DM, Meacham LR, Meeske KA, Mulrooney DA, Ness KK, Oeffinger KC, Sklar CA, Stovall M, van der Pal HJ, Weathers RE, Robison LL, Yasui Y. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol. 2015;33:394-402. [PMID: 25287823 DOI: 10.1200/jco.2014.56.1373] [Cited by in Crossref: 127] [Cited by in F6Publishing: 51] [Article Influence: 15.9] [Reference Citation Analysis]
7 Toro-salazar OH, Ferranti J, Lorenzoni R, Walling S, Mazur W, Raman SV, Davey BT, Gillan E, O’loughlin M, Klas B, Hor KN. Feasibility of Echocardiographic Techniques to Detect Subclinical Cancer Therapeutics–Related Cardiac Dysfunction among High-Dose Patients When Compared with Cardiac Magnetic Resonance Imaging. Journal of the American Society of Echocardiography 2016;29:119-31. [DOI: 10.1016/j.echo.2015.10.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
8 Zeien J, Qiu W, Triay M, Dhaibar HA, Cruz-Topete D, Cornett EM, Urits I, Viswanath O, Kaye AD. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacother 2021;146:112503. [PMID: 34922113 DOI: 10.1016/j.biopha.2021.112503] [Reference Citation Analysis]
9 Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S, Bansal N, Ehrhardt MJ, Armenian SH, Scott JM, Hong B. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovasc Res 2019;115:922-34. [PMID: 30768157 DOI: 10.1093/cvr/cvz031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
10 Bomken S, Skinner R. Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood. Children (Basel) 2015;2:146-73. [PMID: 27417356 DOI: 10.3390/children2020146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
11 Dionne F, Aminkeng F, Bhavsar AP, Groeneweg G, Smith A, Visscher H, Rassekh SR, Ross C, Carleton B. An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines. Pediatr Blood Cancer 2018;65. [PMID: 29271558 DOI: 10.1002/pbc.26887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. J Clin Oncol 2015;33:2639-45. [PMID: 26014292 DOI: 10.1200/JCO.2014.59.4473] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 7.4] [Reference Citation Analysis]
13 Leger KJ, Leonard D, Nielson D, de Lemos JA, Mammen PP, Winick NJ. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy. J Am Heart Assoc 2017;6:e004653. [PMID: 28377429 DOI: 10.1161/JAHA.116.004653] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
14 Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M. Anthracycline-Induced Cardiomyopathy in Adults. Compr Physiol 2015;5:1517-40. [PMID: 26140726 DOI: 10.1002/cphy.c140059] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
15 Narayan HK, Getz KD, Leger KJ. Minimizing cardiac toxicity in children with acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2021;2021:368-75. [PMID: 34889355 DOI: 10.1182/hematology.2021000268] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wzgarda A, Kleszcz R, Prokop M, Regulska K, Regulski M, Paluszczak J, Stanisz BJ. Unknown face of known drugs – what else can we expect from angiotensin converting enzyme inhibitors? European Journal of Pharmacology 2017;797:9-19. [DOI: 10.1016/j.ejphar.2016.12.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
17 Yu C, Pathan F, Tan TC, Negishi K. The Utility of Advanced Cardiovascular Imaging in Cancer Patients-When, Why, How, and the Latest Developments. Front Cardiovasc Med 2021;8:728215. [PMID: 34540922 DOI: 10.3389/fcvm.2021.728215] [Reference Citation Analysis]
18 Mancilla TR, Iskra B, Aune GJ. Doxorubicin-Induced Cardiomyopathy in Children. Compr Physiol 2019;9:905-31. [PMID: 31187890 DOI: 10.1002/cphy.c180017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
19 Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol 2014;165:364-74. [PMID: 24467690 DOI: 10.1111/bjh.12754] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 13.1] [Reference Citation Analysis]